Pharmafile Logo

RotaTeq

Shire Basingstoke

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

A rapid run-down of news in pharma, biotech and healthcare

- PMLiVE

Merck preps regulatory filings for much-needed antibiotic combo

The regimen combines Merck’s own Primaxin with new beta lactamase inhibitor relebactam

- PMLiVE

Merck’s Keytruda meets survival challenge in NSCLC

Data showed that almost 70% of patients on the combo were still alive after 12 months

- PMLiVE

Sanofi backs vaccines unit with €350m Canadian facility

The new plant will make paediatric and booster vaccines

- PMLiVE

GSK hands rare disease assets over to Orchard

The UK pharma group will take a 19.9% stake in its ex-rival

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

- PMLiVE

GSK buys Novartis out of consumer health JV after ditching Pfizer bid

Will pay $13bn for the 36.5% stake owned by the Swiss drug maker

- PMLiVE

GSK joins Reckitt in passing on Pfizer’s consumer health unit

The healthcare business doesn’t meet GSK’s criteria for returns, says Walmsley

- PMLiVE

Ex-GSK CEO Witty named head of pharmacy benefit firm Optum

Current Optum CEO Larry Renfro will move to Optum Ventures as MD

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

The duo will start a series of clinical trials combining the multiple RTK inhibitor and Keytruda

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links